49 results about "Polymannuronic acid" patented technology

The invention provides applications of poly mannuronic acid propyl ester sulfate (PMS) in preparing anti- H1N1 influenza A virus medication. Experiments of the invention prove that PMS not only has great inhibition effect on the neuraminidase of the influenza A virus, but also has relatively good protection effect on canine kidney epithelial cells infected with the H1N1 influenza A virus, and can reduce the replication of the H1N1 virus with an effect that equal to the positive control medication ribavirin. Additionally, the PMS can effectively reduce the death rate of mice infected with the H1N1 influenza A virus and the survival time of the mice are prolonged. The poly mannuronic acid propyl ester sulfate provided by the invention has significant activity of inhibiting the neuraminidase of the H1N1 influenza A virus, and is proved to have good anti- H1N1 influenza A virus activity both in vivo and in vitro experiments, which shows the wide application prospect of the poly mannuronic acid propyl ester sulfate in preparing anti-H1N1 influenza A virus medication.

The invention provides application of mannuronic acid oligomers in preparing medicines, health products or dietary supplements for preventing and treating alcoholic liver injury. Mannuronic acid oligomers with different molecular weights, which are obtained by degrading polymannuronic acid graded and purified from algin, can lower the hepatosomatic index increase caused by alcoholic injury, resist triglyceride and cholesterol increase caused by alcohol, effectively lower glutamic-pyruvic transaminase and glutamic oxaloacetic transaminase increase in serum caused by alcohol, enhance the total oxidation resistance and glutathione level of the serum, lower the mouse drunkenness rate, prolong the mouse drunkenness time, and shorten the sober-up time, thereby implementing the protective action and hangover alleviating function on alcoholic hepatic injury. The products provided by the invention are derived from marine natural products, have the advantages of abundant resources, high industrialization tendency, high safety, high effectiveness and the like, and have wide development and application prospects in the aspects of prevention and treatment of alcoholic hepatic injury, hangover alleviation and liver protection.

The invention relates to a marine oligosaccharide compound with type II diabetes resisting activity, which is a compound which is formed by following steps: taking D-polymannose aldehydic oligosaccharide which comes from sea and contains carboxyl in each oligosaccharide ring, reacting with dilute alkali and chromium salt solution and introducing trivalent chromium ions which is closely relative to the generation and the development of diabetes into oligosaccharide molecules. A pharmacological experiment proves that the product has remarkable effect on accelerating insulin secretion, is not influenced by amylin and has effects on lightening glucose load, improving blood-lipoid metabolism, insulin sensitivity and certain kidney protection and lightening pancreatic injury for type II diabetes rats and mouse. The product of the invention comes from marine natural species, has the advantages of good security, unique structure, low molecular weight, high chromium binding ratio, good oral absorption effect, and the like, can play a hypoglycemic role in a plurality of links and has favorable market application prospect on the aspect of preventing and treating type II diabetes.

The invention discloses an alginate lyase SHA‑3 gene, the nucleotide sequence of which is shown in SEQ ID NO: 1. The invention constructs a prokaryotic expression vector of the alginate lyase SHA‑3 gene, which can be used in The expression product alginate lyase SHA‑3 was obtained in a short period of time, and it has a wide range of substrate specificity. It can use both polymannuronic acid PolyM and polyguluronic acid PolyG as substrates, and the enzyme activity reaches 12U / mg, is a bifunctional enzyme with broad application prospects, the prokaryotic expression vector and the overall expression system of the present invention are easy to operate, and are convenient for industrial production.

The invention discloses a method for preparing mannuronic acid monomer by degrading polymannuronic acid with sulfuric acid. Bio-Gel P10fine or Bio-Gel P6fine gel permeation chromatography is used to separate and purify the degraded oligosaccharide mixture to obtain 10 oligosaccharide components; use thin layer chromatography (TLC), high performance liquid chromatography (HPLC), mass spectrometry (MS) to analyze different components, and prepare mannuronic acid oligosaccharides with a polymerization degree of 1‑10 monomer. The method of the present invention can prepare mannuronic acid oligosaccharide monomers with a degree of polymerization of 1-10, and the purity reaches more than 95%. At the same time, the method uses sulfuric acid as the degradation condition, and anhydrous calcium carbonate is added after degradation, and after stirring and filtering Sulfate ions can be removed directly to avoid secondary desalination during purification. The method is time-consuming, simple and easy to operate, and can be separated and purified in large quantities with good repeatability.

The invention provides an antithrombotic medicament for intravenous injection. The medicament is a modified acidic polysaccharide consisting of only one monosaccharide and has a structural general formula, wherein R is -CH3 or -CH2-CH(OH)-CH3; R' is -H or -SO3Na; each sugar ring has at least one R' which is -SO3Na; n is equal to 2 to 6; when R is -CH3, the compound represented by the structural general formula is an oligomannuronicacid methyl acetate sulfate sodium salt; and when R is -CH2-CH(OH)-CH3, the compound represented by the structural general formula is an oligomannuronicacid proply acetate sulfate sodium salt. The medicament for intravenous injection has obvious anticoagulation, wherein the anticoagulation titer is 17 to 23; rabbit collagen induced platelet aggregation and platelet adhesion are obviously inhibited; and local ischemic brain damage caused by formation of cerebral thrombosis is lessened by inhibiting the formation of cerebral thrombosis and ischemic brain tissues are obviously protected.

The invention discloses a alginate lyase (Alg509) derived from marine bacteria and its gene. At the same time, the method for recombinant expression and preparation of the alginate lyase is also disclosed, which is about to alg509 The gene is cloned into an Escherichia coli expression vector, and the vector is transformed into an Escherichia coli host bacterium to obtain a recombinant engineering strain capable of heterologously expressing the enzyme. The alginate lyase Alg509 disclosed by the present invention has high enzyme activity, the specific enzyme activity can reach more than 48000U / mg, the optimum reaction pH is 10, the optimum reaction temperature is 55°C, and the enzyme activity has no dependence on various metal ions . The enzyme is active on sodium alginate, polyguluronic acid (polyG) and polymannuronic acid (polyM), and can completely degrade sodium alginate to produce fucobiose, fucoidanose, and fucoidan Sugar and other fucoidan oligosaccharides. The enzyme exhibits strong basophilicity, has a certain tolerance to high pH, ​​has a certain potential for industrial application, and can be widely used in agriculture, food, feed additives, medicine and other fields.